- Associated Press•last month
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 43 cents. Losses, adjusted for non-recurring costs, came to 40 cents per share. The drug developer posted revenue ...
- The Wall Street Journal•2 months ago
Pfizer won bankruptcy-court approval to buy the assets of Bind Therapeutics after an auction doubled Pfizer’s starting offer, for a final price of $40 million.
- Business Wire•2 months agoBIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets
BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND’s assets.
BIND Therapeutics, Inc. (BIND)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||0.69 - 0.83|
|52wk Range||0.35 - 1,320.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.39|
|Avg Vol (3m)||692,049|
|Dividend & Yield||N/A (N/A)|